Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter
methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is
limited. The aim of this study is to compare the effect of Etoposide plus Cisplatin and
Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma.